Activating BRAF V600E mutations are also known to occur in subsets of thyroid and colon carcinomas (Davies et al, 2002), and similar to melanoma, the presence of the mutation also predicts for sensitivity to MEK inhibition (Solit et al, 2006; Leboeuf et al, 2008). The gene discussed is MAP2K7; the disease is melanoma.